1. Medtech Insight
  2. >>Business

Start-Up Spotlight: Aria CV Addresses Right-Heart Failure With Purely Mechanical Solution

 
• By Reed Miller

St. Paul-based Aria CV is developing a "passive" pulmonary artery balloon system to treat pulmonary hypertension and impede the development of heart failure. Following a successful first-in-human study, the company is currently developing a feasibility study it expects will lead to a US pivotal trial in several years.

Start-up Spotlight

Aria CV hopes to address pulmonary hypertension, a potentially devastating condition that currently has few treatments, with a unique balloon device that requires no power supply, battery, pump, or synchronization.

Pulmonary hypertension increases "afterload" on the right ventricle, which contributes to right-heart failure, but there are not many options to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Tempus AI Buys Paige. AI For $81.25M To Help Build Largest Oncology Foundation Model

 
• By Marion Webb

Tempus expects its $81.25m acquisition of Paige AI to accelerate building the largest oncology foundation model. With its third deal this year, Tempus expands capabilities across genomics, pathology, and clinical trials.

Terumo’s $1.5Bn Buyout Of OrganOx Vaults Company Into Organ Preservation Market

Terumo will acquire OrganOx for about $1.5bn, adding the only FDA-cleared liver normothermic perfusion device to its portfolio. Analysts don’t expect the buyout to have a significant impact on competition, but the deal marks a strategic shift for Terumo into transplant medicine.

Reports Put $4B Price Tag On Versius Maker CMR. Will This Change Surgical Robot Valuation?

 
• By Barnaby Pickering

The value proposition of surgical robots is quickly changing. Gone is the focus on benefit to patients; instead cost, operative efficiency and surgeon longevity are the new focal points, making deciphering M&A value much more difficult.

Dexcom Nabs Weight Management Indication For Signos CGM

 
• By Malcolm Spicer

Signos links users to Dexcom’s Stelo for glucose readings and historic trends. The app is available in iOS and Android from the firm’s website, where it’s priced at $139 for three-month plan and $129 for a two-month plan, or online app stores.

More from Medtech Insight

Study Finds Public Companies Behind Most Recalled AI Devices

 
• By Elizabeth Orr

A Johns Hopkins University study found publicly traded companies are responsible for 90% of recalled AI-powered medical devices. The study attributes this link to lower clinical validation, especially among smaller companies, and advocates for increased clinical trials to enhance device safety.

Reports Put $4B Price Tag On Versius Maker CMR. Will This Change Surgical Robot Valuation?

 
• By Barnaby Pickering

The value proposition of surgical robots is quickly changing. Gone is the focus on benefit to patients; instead cost, operative efficiency and surgeon longevity are the new focal points, making deciphering M&A value much more difficult.

Four-Year Waits, 60-Page NCDs: Consultant Urges Medicare Overhaul

 
• By Elizabeth Orr

Medicare’s device coverage process is “a system in crisis,” consultant Bruce Quinn warned at the NextGen Dx Summit. He criticized bloated NCDs, stalled advisory committees, and years-long delays, urging CMS to streamline LCDs and adopt a six-month “fast-track” model to speed innovation access.